Fortress Biotech Inc (NASDAQ:FBIO) SVP George Avgerinos sold 25,593 shares of the business’s stock in a transaction that occurred on Tuesday, December 12th. The stock was sold at an average price of $3.59, for a total transaction of $91,878.87. Following the completion of the sale, the senior vice president now owns 409,088 shares of the company’s stock, valued at $1,468,625.92. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.
Fortress Biotech Inc (FBIO) traded down $0.06 during trading hours on Thursday, reaching $3.52. 76,318 shares of the company were exchanged, compared to its average volume of 168,482. Fortress Biotech Inc has a 52 week low of $1.88 and a 52 week high of $5.13. The company has a debt-to-equity ratio of 0.42, a current ratio of 2.69 and a quick ratio of 2.69.
Fortress Biotech (NASDAQ:FBIO) last posted its quarterly earnings results on Thursday, November 9th. The biopharmaceutical company reported ($0.67) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.43) by ($0.24). Fortress Biotech had a negative net margin of 65.80% and a negative return on equity of 61.43%. The firm had revenue of $46.89 million for the quarter, compared to the consensus estimate of $50.75 million. The company’s quarterly revenue was up 4709.2% on a year-over-year basis. equities research analysts expect that Fortress Biotech Inc will post -1.99 EPS for the current fiscal year.
A number of equities research analysts have recently weighed in on the stock. Zacks Investment Research upgraded shares of Fortress Biotech from a “sell” rating to a “hold” rating in a report on Tuesday, October 10th. HC Wainwright set a $11.00 price objective on shares of Fortress Biotech and gave the stock a “buy” rating in a report on Tuesday. Finally, ValuEngine lowered shares of Fortress Biotech from a “hold” rating to a “sell” rating in a report on Friday, December 1st. One investment analyst has rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $11.00.
COPYRIGHT VIOLATION WARNING: This piece was first posted by American Banking News and is the sole property of of American Banking News. If you are reading this piece on another website, it was stolen and reposted in violation of United States & international trademark and copyright law. The legal version of this piece can be accessed at https://www.americanbankingnews.com/2017/12/14/fortress-biotech-inc-fbio-svp-george-avgerinos-sells-25593-shares.html.
About Fortress Biotech
Fortress Biotech, Inc, formerly Coronado Biosciences, Inc, is a biopharmaceutical company. The Company is involved in the development of immunotherapy agents for the treatment of autoimmune diseases and cancer. Its sole product candidate is CNDO-109. The Company is also focused on acquiring, developing and commercializing pharmaceutical and biotechnology products.
Receive News & Ratings for Fortress Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fortress Biotech and related companies with MarketBeat.com's FREE daily email newsletter.